ANI Pharmaceuticals (ANIP) Jefferies 2024 Global Healthcare Conference summary

Financial performance and growth

• Achieved $487 million in 2023 sales, a 54% year-over-year increase, with $229 million in cash as of March 31, 2024.

• Generated $119 million in operating cash flow in 2023 and maintained a 35% CAGR since 2021.

• Q1 2024 sales reached a record $137 million, with adjusted non-GAAP EBITDA at $38 million.

• 2024 guidance projects $520–$542 million in revenue, $135–$145 million in adjusted non-GAAP EBITDA, and $4.26–$4.67 in adjusted non-GAAP EPS.

• Net leverage stands at half a turn of EBITDA, supporting further business development.

Rare disease business and Cortrophin Gel

• Rare disease segment, led by Purified Cortrophin Gel, is the primary growth driver, with 2024 sales guidance of $170–$180 million.

• Cortrophin Gel expanded into new indications: pulmonology and ophthalmology, with strong new patient starts in April and May.

• ACTH market, once $1.2 billion in 2017, is returning to growth, with 2024 projected at $580–$590 million.

• High barriers to entry and limited competition support long-term sustainability.

• M&A efforts focus on rare disease assets in current and adjacent therapeutic areas, prioritizing synergy and sustainable growth.

Generics and established brands

• Generics business delivered $100 million in Q1 2024 sales, supported by six new product launches.

• Growth driven by superior R&D, operational excellence, and a fully U.S.-based manufacturing footprint.

• 2024 R&D spend increased to fuel high single-digit to low double-digit growth.

• Manufacturing sites in Minnesota and New Jersey have strong compliance records and expanded capacity.

• U.S.-based manufacturing provides a competitive edge amid industry supply constraints.